Overview: TPMT4 Test*Introduction: The TPMT4 Test tests for TPMT4 mutation to assess risk for drug toxicity in chemotherapy, helping guide safe treatment dosing. Affecting 1 in 300 patients on thiopurines, TPMT variants pose diagnostic challenges due to variable metabolism. Following 2023 Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, it uses PCR/sequencing for high accuracy, supporting molecular pathology screening. This test is essential for diagnosis, treatment planning, and improving outcomes in oncology.Other Names: TPMT4 Mutation Test, Thiopurine Toxicity Assay.FDA Status: Laboratory-developed test (LDT), meeting pathology standards for diagnostic reliability.Historical Milestone: TPMT4 testing began in the 1990s with research by Weinshilboum, who identified the variant. PCR/sequencing advancements by Illumina improved detection, surpassing earlier genotyping methods.Purpose: Detects TPMT4 mutation status to assess chemotherapy toxicity risk, guides dosing adjustments, and evaluates patients with chemotherapy history, aiming to prevent toxicity.Test Parameters: TPMT4 mutation statusPretest Condition: No special preparation required. Collect whole blood, buccal swab, or saliva. Report history of chemotherapy.Specimen: Whole Blood (EDTA, 3-5 mL), Buccal Swab (sterile swab, 1-2 swabs), Saliva (sterile container, 1-2 mL); 4 mL whole blood in EDTA tube. Transport in a biohazard container.Sample Stability at Room Temperature: 24 hoursSample Stability at Refrigeration: 1 weekSample Stability at Frozen: 1 monthMedical History: Document chemotherapy history. Include current medications or family history.Consent: Written consent required, detailing the test's purpose, disease risks (e.g., toxicity), and sample collection risks.Procedural Considerations: Uses PCR/sequencing to detect mutation, requiring labs with thermal cyclers. Results available in 5-7 days. Performed in labs with strict handling.Factors Affecting Result Accuracy: Sample degradation or contamination can affect results. Medications may not affect results but require correlation.Clinical Significance: Positive mutation suggests toxicity risk, guiding dosing. Early adjustment might prevent adverse effects, while untreated cases lead to complications. Normal results may require standard dosing.Specialist Consultation: Consult an oncologist or pharmacologist for interpretation.Additional Supporting Tests: TPMT enzyme activity, blood counts, or genetic panel to confirm diagnosis.Test Limitations: Specific to TPMT4; correlation with clinical status needed. False negatives possible with other variants.References: CPIC Guidelines, 2023; Clinical Pharmacology & Therapeutics, Weinshilboum RM, 2022.